Research and Markets: The Next 10 Years will see Six Statins Lose Patent Protection with the Potential Loss of over $20 billion Across the Seven Major Markets

Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c22791) has announced the addition of Antidyslipidemics - Cholesterol Absorption of Lipitors Dominance to their offering

The next 10 years will see six statins lose patent protection, with the potential loss of over $20 billion across the seven major markets. However, their established position as first-line therapy will see the major classes maintain volume sales, although price (and hence value) will be driven down as generic competition tries to gain a share of this highly lucrative market.

This report provides country specific event-driven sales forecasts for the period 2005-14 for the US, Japan, France, Germany, Italy, Spain, the UK, and globally. It gives an overview of patient potential and prescribing trends in the antidyslipidemics market based on historical sales data and future key events. The report provides an examination of the country and market specific issues which will impact future sales in the market including generic erosion and class switching. Case studies present the reasons for the success of ezetimibe, and Pfizer's strategy with atorvastatin/torcetrapib to maintain the Lipitor franchise.

Fears of potentially fatal rhabdomyolysis with statin use have led to a significant increase in use of adjunct therapies such as fibrates and nicotinic acid derivatives. However, it is believed their use will plateau and then decline over the next 10 years as attention shifts to newer drug classes. Zetia and Vytorin will dominate second-line therapy in the next 10 years, with Vytorin likely to replace Zetia as second-line therapy of choice. Ezetimibe addresses two unmet needs: provision of HMG-CoA reductase inhibition at lower statin doses and access of "difficult-to-reach" patient populations.

Greater focus on aspects of the lipid profile in addition to LDL, such as TG and HDL is creating an opportunity for combination therapies. Atorvastatin + torcetrapib is expected to have a major impact on the dyslipidemia market and is expected to compete with both atorvastatin and the simvastatin + ezetimibe combination, Vytorin.

Benefits of this report:

- View independent, event-driven forecasts for key antidyslipidemic products and classes across the seven major markets.
- Identify possible future strategies to maximize product potential and compete against new adjunctive therapies.
- Redesigned report template presents executive summary in an accessible PowerPoint format allowing rapid access to the key insights.

For more information visit http://www.researchandmarkets.com/reports/c22791

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980